Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
Fabrizio Martora, Massimiliano Scalvenzi, Teresa Battista, Luigi Fornaro, Luca Potestio, Angelo Ruggiero, Matteo Megna Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, ItalyCorrespondence: Fabrizio Martora, Section of Dermatology - Depart...
Saved in:
Main Authors: | Martora F (Author), Scalvenzi M (Author), Battista T (Author), Fornaro L (Author), Potestio L (Author), Ruggiero A (Author), Megna M (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022) -
Long-Term Efficacy of Guselkumab in an Adolescent Hidradenitis Suppurativa Patients: A Case Report
by: Martora F, et al.
Published: (2024) -
Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study
by: Martora F, et al.
Published: (2024) -
Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience
by: Martora F, et al.
Published: (2023) -
Secukinumab for Severe Hidradenitis Suppurativa in a Patient on Haemodialysis: Efficacy and Safety on 300 mg Every 2 Weeks Administration – A Case Report
by: Martora F, et al.
Published: (2024)